TENX
Tenax Therapeutics, Inc.11.16
+0.55+5.18%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
69.68MP/E (TTM)
-Basic EPS (TTM)
-0.74Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
EPO patent grant for TNX-103
Tenax Therapeutics scored a key win as the European Patent Office signaled intent to grant a patent protecting TNX-103 (oral levosimendan) and other formulations for treating PH-HFpEF through at least December 2040. This bolsters IP in Europe, matching North American patient prevalence, while the company gears up for its LEVEL-2 Phase 3 trial recruiting there this year. Patent covers diverse doses and combos with cardiovascular drugs. Yet clinical trials carry inherent risks.
8-K
Expands levosimendan license rights
Tenax Therapeutics expanded its license from Orion Corporation on September 3, 2025, gaining exclusive worldwide rights to develop, commercialize, and manufacture orally-administered levosimendan products, building on existing subcutaneous rights. Orion will supply levosimendan for oral development at low triple-digit thousands in Euros per kilogram. This broadens Tenax's pipeline in critical care. Supply terms ensure GMP compliance.
8-K
Q2 loss widens on trial advances
Tenax Therapeutics reported a Q2 2025 net loss of $10.8 million, up from $3.6 million last year, driven by $6.1 million in R&D expenses for its Phase 3 LEVEL study of TNX-103 in PH-HFpEF patients and preparations for the global LEVEL-2 trial. Cash reserves stand at $105.5 million, funding operations through 2027. Enrollment in LEVEL, targeting 230 patients, nears completion in H1 2026, with topline data in H2. Patent allowance in Canada bolsters IP to 2040.
ATXS
Astria Therapeutics, Inc.
12.87-0.05
AURX
Nuo Therapeutics, Inc.
2.00-0.15
BIXT
Bioxytran, Inc.
0.07+0.00
BLRX
BioLineRx Ltd.
3.01-0.17
IMA
ImageneBio, Inc.
6.25+0.08
INBX
Inhibrx Biosciences, Inc.
81.57+5.36
MRKR
Marker Therapeutics, Inc.
1.27-0.12
TBPH
Theravance Biopharma, Inc.
17.53-0.24
TNGX
Tango Therapeutics, Inc.
8.96-0.16
TNYA
Tenaya Therapeutics, Inc.
0.77-0.03